NASDAQ:PROF

Profound Medical (PROF) Stock Price, News & Analysis

$8.09
+0.06 (+0.75%)
(As of 11:12 AM ET)
Today's Range
$8.06
$8.14
50-Day Range
$7.70
$9.20
52-Week Range
$7.11
$15.49
Volume
1,007 shs
Average Volume
40,101 shs
Market Capitalization
$197.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.58

Profound Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
80.3% Upside
$14.58 Price Target
Short Interest
Healthy
1.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Profound Medical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.17) to ($1.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

536th out of 908 stocks

Surgical & Medical Instruments Industry

62nd out of 97 stocks

PROF stock logo

About Profound Medical Stock (NASDAQ:PROF)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

PROF Stock Price History

PROF Stock News Headlines

War Over Taiwan? Protect Your Wealth NOW
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
Accuryn Medical Announces Leadership Transition
War Over Taiwan? Protect Your Wealth NOW
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
PRN:CA Profound Medical Corp.
See More Headlines
Receive PROF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/26/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PROF
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.58
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+81.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-28,570,000.00
Net Margins
-396.85%
Pretax Margin
-398.62%

Debt

Sales & Book Value

Annual Sales
$7.20 million
Book Value
$1.28 per share

Miscellaneous

Free Float
24,058,000
Market Cap
$196.17 million
Optionable
Optionable
Beta
0.80
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Arun Swarup Menawat MBA (Age 69)
    Ph.D., Chairman of the Board & CEO
    Comp: $551.88k
  • Mr. Rashed Dewan (Age 56)
    Chief Financial Officer
    Comp: $250.37k
  • Dr. Mathieu Burtnyk (Age 42)
    Chief Operating Officer
    Comp: $246.1k
  • Mr. Hartmut Warnken (Age 51)
    Chief Commercial Officer of Outside US
    Comp: $224.93k
  • Mr. Abbey Goodman (Age 41)
    Chief Commercial Officer of US
    Comp: $353.75k
  • Mr. Stephen Kilmer
    Investor Relations
  • Mr. Jacques F. Cornet (Age 68)
    Senior VP & Product Leader Sonalleve
  • Mr. Matthew Sobczyk C.A.
    CPA, Assistant Corporate Controller
  • Mr. Levant Tinaz
    Software Developer

PROF Stock Analysis - Frequently Asked Questions

Should I buy or sell Profound Medical stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last twelve months. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PROF shares.
View PROF analyst ratings
or view top-rated stocks.

What is Profound Medical's stock price target for 2024?

3 brokers have issued 1-year price objectives for Profound Medical's stock. Their PROF share price targets range from $11.00 to $20.00. On average, they expect the company's share price to reach $14.58 in the next twelve months. This suggests a possible upside of 80.3% from the stock's current price.
View analysts price targets for PROF
or view top-rated stocks among Wall Street analysts.

How have PROF shares performed in 2024?

Profound Medical's stock was trading at $8.49 at the beginning of 2024. Since then, PROF shares have decreased by 4.7% and is now trading at $8.09.
View the best growth stocks for 2024 here
.

When is Profound Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PROF earnings forecast
.

How were Profound Medical's earnings last quarter?

Profound Medical Corp. (NASDAQ:PROF) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.14. The firm had revenue of $2.01 million for the quarter, compared to the consensus estimate of $1.90 million. Profound Medical had a negative trailing twelve-month return on equity of 70.18% and a negative net margin of 396.85%.

Who are Profound Medical's major shareholders?

Profound Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (2.56%).

How do I buy shares of Profound Medical?

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROF) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners